News

Pharmamar’s new  candidate avails
Enlarge image

OncologySpain

Pharmamar’s new candidate avails

03.10.2012 - Clinical data presented at a Congress in Vienna shows that a new Pharmamar drug could step up to the success of its paragon Yondelis.

Pharmamar S.A. from Colmenar Viejo is part of Spain’s largest biotech Zeltia S.A. It is known for its marine tunicate-derived anti-cancer drug Yondelis. But there is another potentially marketable drug named PM01183 (lurbinectedin) in the pipeline. On 30 September, new clinical data was presented at the 37th Congress of the European Society of Molecular Oncology (ESMO) in Vienna. Results from the first part of a two-stage Phase II study in patients with platinum-resistant or refractory ovarian cancers were well-perceived, where a confirmed response to the treatment was observed in 6 out of 22 patients. Moreover, the disease had only progressed in 6 patients at the first evaluation, which means that the tumour remained stable in the remaining 10 patients (disease control rate: 73%). The drug showed no toxicity-related problems. The second stage was launched in April with the enrolment of 60 additional patients, who will be randomised to either the PM01183 arm or the active comparator arm where GSK’s topotecan is given.

Other indications where PM01183’s potential is scrutinised include non-small-cell lung carcinoma and breast cancer. Data of a Phase Ib study also presented at the meeting suggest that a combination of PM01183 with the nucleoside analogue gemcitabine improves the anti-tumour activities in the first mentioned indication when compared to treatments with each drug alone. The latter indication is dealt with in a Phase II study with metastatic breast cancer (MBC) patients which started in June this year. Here, patients are stratified into one group where the women have certain deleterious germline mutations in BRCA1/2 and another with woman without such mutations. Pharmamar wants to show that PM01183 works for BRCA 1/2-associated MBCs.

Pharmamar also tries to widen the scope of Yondelis, the first cancer medication ever to be developed in Spain. Moving from 2nd line to 1st line indications Yondelis (trabectedin) is currently under investigation for its strength to fight non-operable and/or metastatic soft tissue sarcomas. In the trial named GEIS-20 standard doxorubicin treatment is compared against a doxorubicin-trabectedin-combination. Results of the Phase II, open label, randomised study with 182 patients are expected in Q4/12.

© eurobiotechnews.eu/ml

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3297.5%
  • GW PHARMACEUTICALS (UK)419.75 GBP642.9%
  • PAION (D)2.77 EUR319.7%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.4%

No liability assumed, Date: 28.07.2014